Drug Discovery

In our DRUG DISCOVERY small molecules, we have specialized in EPIGENETIC TARGETS.

Epigenetics can be defined as “the study of heritable changes in genome function that occur without a change in DNA sequence”. These changes mainly occur due to variations in the structure of chromatin that silence or activate whole regions of the chromosome and all the genes that reside in this region. These variations are caused by post-translational modifications on histones, the proteins that serve as scaffold for the DNA to conform the chromatin.
The main post-translational modifications on histones are acetylation-deacetylation  and methylation-demethylation events and are controlled by specific enzymes. Therefore, all these protein have high potential for therapeutic applications.

Oryzon is a global leader in the area of histone demethylation with 17 patents and has a first in class program based on inhibitors of Lysine demethylase-1 (LSD1).